TAA06 Injection in the Treatment of Patients With B7-H3-positive Relapsed/ Refractory Neuroblastoma

NCT05562024 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

B7-H3-positive Relapsed/ Refractory Neuroblastoma

Interventions

BIOLOGICAL: T cell injection targeting B7-H3 chimeric antigen receptor

Sponsor

PersonGen BioTherapeutics (Suzhou) Co., Ltd.

Collaborators

[object Object]
[object Object]